Ossifi Inc is a privately held company based in Overland Park, KS, specializing in the development of innovative bone building therapies. With a focus on the validated target Sclerostin, Ossifi is developing a first-in-class bone building small molecule that outperforms current standard of care antiresorptives by directly acting on bone cells to achieve a controlled double-digit increase in bone density, quickly restoring and maintaining healthy bone levels.
Founded in 2006, Ossifi has capitalized its operations through convertible notes and non-dilutive grants, and its proprietary development approach ensures a safe therapeutic with fewer adverse effects in clinical trials. Committed to advancing safer and more effective bone building therapies, Ossifi offers accelerated clinical development opportunities and proprietary approaches to developing novel therapeutics.
Generated from the website